Navigation Links
China Shenghuo to Resume Trading on NYSE Alternext US LLC
Date:12/9/2008

KUNMING, China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today announced that the Company's shares would resume trading on NYSE Alternext US LLC ("NYSE Alternext US" or the "Exchange") at the open of business on Tuesday, December 9th. The Company's shares will continue to trade under the symbol "KUN."

"We are delighted that the Exchange has decided to allow our shares to resume trading," said Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo. "The relisting of our shares marks a major milestone for the Company and it offers a measure of reassurance to both our retail and institutional investors that we have succeeded in putting a very challenging period in the Company's history behind us."

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi- based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory inquiry or proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; potential adverse effects to the Company's financial condition, results of operations or prospects as a result of possible changes to or restatements of prior period financial statements; risks arising from potential weaknesses or deficiencies in the Company's internal control over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    China Shenghuo Pharmaceutical Holdings, Inc.
     Mr. Changhua Mu
     Securities Affairs Representative
     Tel:   +86-871-728-2698
     Email: c.mu@chinashenghuo.net

    Grayling Global
     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414
     Email: echeung@hfgcg.com

'/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
2. China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs
3. Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources Private Sourcing Events
4. Diagnosis and Drug Treatment of Alzheimers Disease in China is Low and Will Remain Low Through 2012
5. China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO
6. Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products : Government and Industry Increase Contaminant Testing to Increase Food Safety
7. CCID Consulting Discusses Chinas Medical Equipment Market
8. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
9. China Nepstar Chain Drugstore Reports Third Quarter 2008 Results
10. China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008
11. ChinaBio(R) Inaugural Partnering Forum Scheduled for June 2009 in Shanghai, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Bacteria and fungi are probably not the first ingredients that come to mind ... right microorganisms in your diet can actually improve health outcomes. And the good news is ... topic of a new peer-reviewed paper led by Maria Marco, Ph.D. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental ... want straight teeth without the extensive time commitment and aesthetic disadvantages of traditional ... a referral. A custom-designed series of virtually invisible aligners are created for each ...
(Date:3/27/2017)... Ohio (PRWEB) , ... March 27, 2017 , ... New ... OH to replace their missing teeth can now have them placed by Dr. Manju ... the latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of the ... Sudeep Roy, MD, was recently published in the American Journal of Cosmetic Surgery. ... Drs. Buckingham and Roy’s study on the use of Electro Lube during the facelift ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
(Date:3/27/2017)... -- A new survey from the American Association ... Program (CBP) significantly reduced beneficiary choice and access to ... forces beneficiaries to switch to unfamiliar or unsuitable testing ... AADE,s survey is the latest in a continuous ... the inherent problems with the CBP. Last year, a ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com ... Based ... adult use in states where cannabis is legal will generate $655 ... million will be from cannabis specific taxes, such as ... $96 million will be earned from state sales taxes that are ...
Breaking Medicine Technology: